Characteristics of patients who received LTx
Patient no. . | Age at LTx, y/sex . | Pre-LTx EBV serostatus . | Localization of PTLD . | Time from LTx to PTLD, mo . | Conversion of IS prior to PTLD* . | CMV serostatus, recipient/donor . | Treatment for CMV . |
---|---|---|---|---|---|---|---|
1 | 22/M | − | lung | 2 | — | −/+ | gancyclovir |
2 | 55/F | + | stomach | 19 | CsA to FK506 | −/+ | gancyclovir |
3 | 49/F | + | intestine | 32 | — | +/− | |
4 | 39/M | + | nasopharynx | 55 | — | −/− | |
5 | 43/M | + | liver | 67 | — | +/− | |
6 | 53/F | + | mouth | 78 | CsA to FK506 | −/+ | gancyclovir |
7 | 34/F | + | — | — | — | +/+ | |
8 | 54/F | + | — | — | — | +/− | gancyclovir |
9 | 35/M | − | — | — | — | +/− | |
10 | 55/M | + | — | — | — | −/− | |
11 | 49/F | + | — | — | — | −/− | |
12 | 25/F | + | — | — | — | +/− | |
13 | 50/M | + | — | — | — | +/+ | gancyclovir/foscavir/ immunoglobulines |
14 | 33/M | + | — | — | — | −/− |
Patient no. . | Age at LTx, y/sex . | Pre-LTx EBV serostatus . | Localization of PTLD . | Time from LTx to PTLD, mo . | Conversion of IS prior to PTLD* . | CMV serostatus, recipient/donor . | Treatment for CMV . |
---|---|---|---|---|---|---|---|
1 | 22/M | − | lung | 2 | — | −/+ | gancyclovir |
2 | 55/F | + | stomach | 19 | CsA to FK506 | −/+ | gancyclovir |
3 | 49/F | + | intestine | 32 | — | +/− | |
4 | 39/M | + | nasopharynx | 55 | — | −/− | |
5 | 43/M | + | liver | 67 | — | +/− | |
6 | 53/F | + | mouth | 78 | CsA to FK506 | −/+ | gancyclovir |
7 | 34/F | + | — | — | — | +/+ | |
8 | 54/F | + | — | — | — | +/− | gancyclovir |
9 | 35/M | − | — | — | — | +/− | |
10 | 55/M | + | — | — | — | −/− | |
11 | 49/F | + | — | — | — | −/− | |
12 | 25/F | + | — | — | — | +/− | |
13 | 50/M | + | — | — | — | +/+ | gancyclovir/foscavir/ immunoglobulines |
14 | 33/M | + | — | — | — | −/− |
IS indicates immune suppression; M, male; F, female; +, seropositive; −, seronegative; and CsA, cyclosporine A.
Indicates conversion from CsA to FK506 before presentation of PTLD.